A retail base who are (by the most part) rusted on, and in particular the T20, can also be seen as a positive.
Ultimately, recent history has shown key milestones being met, so I would point to those rather than the shareholder base.
But, as you say, things should see movement quickly once clinical trials are moving.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.20 |
Change
0.030(2.56%) |
Mkt cap ! $203.2M | |||
| Open | High | Low | Value | Volume |
| $1.20 | $1.20 | $1.20 | $7.122K | 5.935K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 17143 | $1.20 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.22 | 3199 | 2 |
View Market Depth
| Last trade - 09.59am 02/07/2025 (20 minute delay) ? |
| RAC (ASX) Chart |